Vanguard Group
DMAC icon

Vanguard Group’s DiaMedica Therapeutics DMAC Stock Holding History

Vanguard Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.76M Buy
723,120
+58,545
+9% +$438K ﹤0.01% 3201
2025
Q3 		$4.57M Sell
664,575
-870,479
-57% -$4.72M ﹤0.01% 3308
2025
Q2 		$5.99M Buy
1,535,054
+183,587
+14% +$716K ﹤0.01% 3145
2025
Q1 		$5.12M Buy
1,351,467
+109,360
+9% +$625K ﹤0.01% 3161
2024
Q4 		$6.74M Buy
1,242,107
+193,078
+18% +$911K ﹤0.01% 3143
2024
Q3 		$4.4M Buy
1,049,029
+31,627
+3% +$117K ﹤0.01% 3314
2024
Q2 		$3M Buy
1,017,402
+3,880
+0.4% +$10.6K ﹤0.01% 3434
2024
Q1 		$2.81M Buy
1,013,522
+211,351
+26% +$614K ﹤0.01% 3488
2023
Q4 		$2.28M Buy
802,171
+13,382
+2% +$33.1K ﹤0.01% 3557
2023
Q3 		$2.04M Buy
788,789
+5,800
+0.7% +$18.6K ﹤0.01% 3573
2023
Q2 		$3.38M Hold
782,989
– – ﹤0.01% 3474
2023
Q1 		$1.2M Hold
782,989
– – ﹤0.01% 3862
2022
Q4 		$1.24M Buy
782,989
+349
+0% +$470 ﹤0.01% 3836
2022
Q3 		$971K Hold
782,640
– – ﹤0.01% 4010
2022
Q2 		$1.58M Hold
782,640
– – ﹤0.01% 3910
2022
Q1 		$1.96M Sell
782,640
-3,912
-0.5% -$11.1K ﹤0.01% 3967
2021
Q4 		$2.93M Sell
786,552
-984
-0.1% -$3.86K ﹤0.01% 3883
2021
Q3 		$3.16M Buy
787,536
+1,270
+0.2% +$4.86K ﹤0.01% 3893
2021
Q2 		$3.5M Sell
786,266
-60,047
-7% -$492K ﹤0.01% 3768
2021
Q1 		$7.74M Buy
846,313
+66,415
+9% +$621K ﹤0.01% 3299
2020
Q4 		$7.91M Buy
779,898
+438,054
+128% +$2.4M ﹤0.01% 3117
2020
Q3 		$1.45M Buy
341,844
+100,027
+41% +$529K ﹤0.01% 3577
2020
Q2 		$1.68M Sell
241,817
-123
-0.1% -$549 ﹤0.01% 3479
2020
Q1 		$677K Buy
241,940
+160,885
+198% +$665K ﹤0.01% 3603
2019
Q4 		$393K Hold
81,055
– – ﹤0.01% 3838
2019
Q3 		$166K Buy
81,055
+46,817
+137% +$151K ﹤0.01% 3979
2019
Q2 		$170K Buy
+34,238
New +$118K ﹤0.01% 4001

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group's DMAC Position: Q4 2025 in Review

Vanguard Group increased its DiaMedica Therapeutics (DMAC) stake by 8.8% in Q4 2025, buying an estimated $438K and bringing the position to 723,120 shares worth $5.76M. The position accounts for ﹤0.01% of the portfolio, ranked #3201.

Vanguard Group first reported a position in DMAC in Q2 2019 and has held it in 27 quarters since. The position peaked at $7.91M in Q4 2020. 92 funds tracked by Wall St. Rank hold DMAC as of Q4 2025.

  • Vanguard Group held 723,120 shares of DiaMedica Therapeutics worth $5.76M as of Q4 2025.
  • Vanguard Group bought 58,545 DiaMedica Therapeutics shares in Q4 2025, an estimated $438K.
  • DiaMedica Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3201 holding.
  • Vanguard Group first reported a position in DiaMedica Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Vanguard Group's DiaMedica Therapeutics position peaked at $7.91M in Q4 2020.
  • 92 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.